Trials / Completed
CompletedNCT01923207
A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects
A Phase 1, Double-Blind, Single Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 (Recombinant Fully Human Antibody Inhibitor of Plasma Kallikrein) in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety and tolerability of the study drug (DX-2930) administered subcutaneously in healthy subjects. Subjects will be randomized to receive DX-2930 or placebo.
Detailed description
Approximately 32 healthy subjects will be randomized to receive DX-2930 or placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DX-2930 | |
| DRUG | Placebo | placebo, subcutaneous administration |
Timeline
- Start date
- 2013-08-12
- Primary completion
- 2014-01-07
- Completion
- 2014-01-07
- First posted
- 2013-08-15
- Last updated
- 2021-05-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01923207. Inclusion in this directory is not an endorsement.